STOCK TITAN
  1. Home
  2. Sec-filings
  3. MRMD
  4. [Form 4] MARIMED INC. Insider Trading Activity

MariMed (MRMD) CEO reports RSU vesting with shares withheld for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

MariMed Inc. President and CEO Jon R. Levine reported routine equity compensation activity involving restricted stock units. On May 7, 2026, RSUs converted into 75,000 shares of common stock. To cover tax obligations tied to this vesting, the issuer withheld 25,988 shares, a tax-withholding disposition rather than an open-market sale.

Following these transactions, Levine directly holds 21,207,986 shares of MariMed common stock. A separate family trust holds 6,684,640 shares for the benefit of his spouse and children, and he disclaims beneficial ownership of those trust-held securities.

Positive

  • None.

Negative

  • None.
Insider Levine Jon R
Role President and CEO
Type Security Shares Price Value
Exercise Restricted Stock Units (RSU) 75,000 $0.00 --
Exercise Common stock 75,000 $0.00 --
Tax Withholding Common stock 25,988 $0.0873 $2K
holding Common stock -- -- --
Holdings After Transaction: Restricted Stock Units (RSU) — 75,000 shares (Direct, null); Common stock — 21,233,974 shares (Direct, null); Common stock — 6,684,640 shares (Indirect, By the Jon Levine Family Trust)
Footnotes (1)
  1. RSUs convert to shares of common stock on a one-for-one basis. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. These RSUs were granted on March 7, 2023; the remaining RSUs under this grant will vest on November 7, 2026, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
RSUs converted 75,000 shares Restricted Stock Units converting into common stock on May 7, 2026
Shares withheld for taxes 25,988 shares Withheld by issuer to satisfy tax obligations on RSU vesting
Direct holdings after transaction 21,207,986 shares MariMed common stock directly held by Jon Levine after Form 4 transactions
Family trust holdings 6,684,640 shares Shares held by a trust for spouse and children; beneficial ownership disclaimed
Tax-withholding price $0.0873 per share Price per share used for the 25,988-share tax-withholding disposition
Restricted Stock Units (RSU) financial
"Restricted Stock Units (RSU) convert to shares of common stock on a one-for-one basis."
tax withholding obligations financial
"Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs."
Section 16 regulatory
"the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose."
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion with code M for RSUs and common stock."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Levine Jon R
(Last)(First)(Middle)
C/O MARIMED INC.
10 OCEANA WAY
(Street)
NORWOOD, MASSACHUSETTS 02062
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common stock05/07/2026M75,000A$0(1)21,233,974D
Common stock05/07/2026F25,988(2)D$0.087321,207,986D
Common stock6,684,640IBy the Jon Levine Family Trust(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units (RSU)(1)05/07/2026M75,000 (4) (4)Common Stock, par value $.001 per share75,000$075,000D
Explanation of Responses:
1. RSUs convert to shares of common stock on a one-for-one basis.
2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. These shares are held in trust for the benefit of the Reporting Person's spouse and children. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
4. These RSUs were granted on March 7, 2023; the remaining RSUs under this grant will vest on November 7, 2026, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.
Remarks:
/s/ Jon R. Levine05/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did MariMed (MRMD) CEO Jon Levine report?

Jon Levine reported RSU-related equity activity. On May 7, 2026, 75,000 restricted stock units converted into common shares, and 25,988 shares were withheld by MariMed to satisfy tax obligations associated with the RSU vesting, a routine compensation-related event.

How many MariMed (MRMD) shares does Jon Levine hold after this Form 4?

After these transactions, Jon Levine directly holds 21,207,986 MariMed common shares. An additional 6,684,640 shares are held in a family trust for his spouse and children, for which he disclaims beneficial ownership under Section 16 reporting rules.

Were Jon Levine’s MariMed (MRMD) transactions open-market buys or sells?

The reported activity was not open-market trading. It reflects RSUs converting into 75,000 common shares and 25,988 shares withheld by MariMed for taxes. The tax withholding is classified as a disposition but does not represent a market sale decision.

What does the tax-withholding entry on Jon Levine’s MariMed (MRMD) Form 4 mean?

The tax-withholding entry shows 25,988 shares were retained by MariMed to pay tax obligations when RSUs vested. This reduces the number of shares issued to Levine but is a mechanical tax payment method, not an open-market sale of stock.

How do Jon Levine’s family trust holdings in MariMed (MRMD) work?

A family trust holds 6,684,640 MariMed shares for the benefit of Jon Levine’s spouse and children. The Form 4 states he disclaims beneficial ownership of these trust-held shares, meaning they are reported for transparency but not treated as his personal holdings.